The Business Research Company’s Pergoveris Market Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035
LONDON, GREATER LONDON , UNITED KINGDOM, November 9, 2026 /EINPresswire.com/ — The Pergoveris market is set to evolve significantly in the coming years, influenced by advancements in fertility treatments and growing awareness surrounding reproductive health. By examining the past trends and future projections, we can better understand the factors steering this market and the regions leading its growth.
Market Size and Growth Forecast for the Pergoveris Market from 2026 to 2030
During the historical period, the Pergoveris market expanded due to factors such as increased diagnosis of gonadotropin deficiencies, a rise in assisted reproductive clinics, improved IVF treatment success rates, availability of recombinant hormone technologies, and heightened infertility awareness. Looking ahead, the market’s growth is projected to be driven by greater demand for advanced IVF protocols, a stronger focus on precision hormone therapies, growth in fertility tourism, wider use of patient-friendly injectable forms, and increased investments in reproductive biotechnology. Key trends expected to shape the market include growing use of recombinant hormone therapies, higher demand for IVF and assisted reproductive technology (ART) procedures, adoption of injectable pen formulations, expansion of precision fertility treatments, and enhanced management of hormone deficiencies.
Download a free sample of the pergoveris market report:
https://thebusinessresearchcompany.com/sample_request?id=73447233&type=smp&name=Pergoveris%20Market%20Report%202026&utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Nov_PR
Understanding Pergoveris and Its Role in Fertility Treatments
Pergoveris is a biologic medication designed for women experiencing severe gonadotropin deficiency, a condition characterized by insufficient production of follicle-stimulating hormone (FSH) and luteinizing hormone (LH). This drug combines recombinant versions of FSH and LH to stimulate the ovaries, encouraging the development of mature eggs necessary for assisted reproductive technologies like in vitro fertilization (IVF). By promoting follicular growth and ovulation, Pergoveris supports women undergoing fertility treatments to enhance their chances of conception.
Key Factors Driving the Growth of the Pergoveris Market
The rising prevalence of infertility is a major factor propelling the Pergoveris market forward. Infertility, defined as the inability to conceive or sustain a pregnancy to term, has been increasing due to delayed childbearing, lifestyle choices, exposure to environmental toxins, and a growing incidence of medical conditions such as polycystic ovary syndrome (PCOS) and endometriosis. Pergoveris aids these patients by stimulating ovarian function through its combination of FSH and LH, facilitating egg development in women facing severe gonadotropin deficiency. For example, in April 2023, the World Health Organization reported that about 17.5% of adults worldwide, roughly one in six individuals, experience infertility, underscoring the expanding patient base driving demand for Pergoveris.
View the full pergoveris market report:
https://thebusinessresearchcompany.com/report/pergoveris-global-market-report?utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Nov_PR
Increasing Use of IVF Procedures Act as a Catalyst for Pergoveris Market Expansion
The growing popularity of IVF treatments is another significant driver for the Pergoveris market. IVF involves fertilizing an egg with sperm outside the body and implanting the resulting embryo into the uterus, benefitting individuals or couples who struggle with conception. More people are turning to IVF as they delay having children due to career, education, or lifestyle considerations, which often leads to age-related fertility challenges. Pergoveris plays a vital role in enhancing IVF outcomes by supporting controlled ovarian stimulation in patients with low ovarian response. For instance, the Human Fertilisation & Embryology Authority in the UK reported that in 2023, 52,400 patients underwent more than 77,500 IVF cycles at licensed clinics, with egg freezing cycles rising from 4,700 in 2022 to 6,900 in 2023, accounting for 7% of all cycles. This increasing adoption of IVF procedures is fueling the demand for Pergoveris.
Regional Overview of the Pergoveris Market
In 2025, Europe led the Pergoveris market in terms of size. However, the Asia-Pacific region is expected to demonstrate the fastest growth during the forecast period. The market analysis includes key geographic areas such as Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, offering a thorough view of regional market dynamics and opportunities.
New additions to our 2026 reports:
• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel-based forecasting dashboards
• Market hotspots infographics
• Key technologies and future trend analysis
• Updated graphics and tables
Speak With Our Expert:
Saumya Sahay
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: marketing@tbrc.info
The Business Research Company – www.thebusinessresearchcompany.com
Follow Us On:
• LinkedIn: https://in.linkedin.com/company/the-business-research-company
Oliver Guirdham
The Business Research Company
+44 7882 955267
info@tbrc.info
Visit us on social media:
LinkedIn
Facebook
X
Legal Disclaimer:
EIN Presswire provides this news content “as is” without warranty of any kind. We do not accept any responsibility or liability
for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this
article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Media gallery
